Aldevron has been serving the biotechnology industry by providing high-quality plasmid DNA, mRNA, proteins, and antibodies for nearly 20 years. Personalized medicine requires manufacturing multiple products concurrently on very short timescales. We are using our breadth and depth of experience to develop innovative manufacturing processes that meet these challenges as well as quality and regulatory requirements. These new products and services are supporting our clients from early discovery research through clinical trials and commercialization. www.aldevron.com
Ichor is dedicated to the clinical application and commercialization of its TriGrid® electroporation technology for the delivery of nucleic acid based biologics to treat numerous disease indications including cancer, chronic viral infections, HIV, and multiple biodefense agents… Read More
Natera is a leader in non-invasive testing of circulating cell-free DNA (cfDNA) in the blood, and has run more than a million cfDNA tests. We recently introduced SignateraTM, a novel circulating tumor DNA (ctDNA) technology that analyzes and tracks mutations specific to an individual’s tumor (“tumor signatures”). It has demonstrated high sensitivity and specificity for ctDNA detection and monitoring, and has the potential to measure treatment response, detect residual disease, and identify recurrence in research.
PGDx is empowering the fight against cancer, unlocking actionable information and revolutionizing cancer medicine through innovative genomic technologies. These novel technologies precisely identify and characterize unique genomic alterations in tumors. PGDx is working toward broad patient access through both a CLIA-certified facility providing comprehensive genomic services and technology transfer solutions enabling other molecular laboratories to easily internalize testing. PGDx is committed to developing a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide. www.pgdx.com
Personalis, Inc. provides genomic solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. Our patented ACE Technology improves every step in the sequencing process, from nucleic acid extraction, to sequencing, to data analytics. This delivers augmented coverage of difficult-to-sequence genomic regions that are missed with conventional sequencing techniques. This comprehensive approach provides data of the highest quality to enable the rational design and development of effective cancer immunotherapies. www.personalis.com
OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.
Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.